The primary goal of the Quality Assurance Review Center is to maintain a responsive, supportive Quality Assurance Program in Radiotherapy for Cooperative Groups. We wish to continue development and implementation of the Program, since it has proven effective in improving the performance of the many gains accomplished in the past decade, leading to improvements in Group performance and with an elevation in sophistication of the Radio-therapy and Physics community in supporting clinical trials, our program, in the future, should take advantage of the improvements without losing ground in the process. In this grant cycle, we propose to undertake a modernization of our Data Management system. We will improve methods of data transfer to Group Investigators and Statistical Offices, with a wide rang of formats. We further propose to reorient Physics support for Group trials by modifying their participation in the development of protocols, in the way Physics data is accumulated and develop a novel approach to the study of radiation effects. The QARC has acted as a research resource for the Cooperative Groups; we are proposing to establish this as a recognized function at QARC. This includes developing normal tissue protocol questions. Secondly, because of the robust data-base that we have developed, we can work with Group Investigators and Statistical Offices to make available subsets of our data for correlative analyses of the radiotherapy performance as it relates to outcome. Because of QARC's recognized ability for Data Management, we have accepted responsibility for accumulation of Diagnostic Imaging data not necessarily a component of the section on Data Management for Diagnostic Imaging materials to support Group trials. Since its initiation a decade ago, QARC has responded to a demonstrated need of the Radiotherapy community in Cooperative Group trials and we propose to continue to be responsive to the changing needs during the period of this grant proposal.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA029511-12
Application #
3557077
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1989-08-15
Project End
1995-12-31
Budget Start
1991-04-16
Budget End
1991-12-31
Support Year
12
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Roger Williams Hospital
Department
Type
DUNS #
City
Providence
State
RI
Country
United States
Zip Code
02908
FitzGerald, Thomas J; Bishop-Jodoin, Maryann (2018) Hodgkin Lymphoma: Differences in Treatment Between Europe and the United States/North America: Evolving Trends in Protocol Therapy. Clin Med Insights Oncol 12:1179554918754885
O'Neill, Allison F; Towbin, Alexander J; Krailo, Mark D et al. (2017) Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group. J Clin Oncol 35:3465-3473
Katzenstein, Howard M; Furman, Wayne L; Malogolowkin, Marcio H et al. (2017) Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee. Cancer 123:2360-2367
Garg, Madhur K; Zhao, Fengmin; Sparano, Joseph A et al. (2017) Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 35:718-726
Sparano, Joseph A; Lee, Jeannette Y; Palefsky, Joel et al. (2017) Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial. J Clin Oncol 35:727-733
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Trippett, Tanya M; Schwartz, Cindy L; Guillerman, R Paul et al. (2015) Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report. Pediatr Blood Cancer 62:60-4
Dharmarajan, Kavita V; Friedman, Debra L; Schwartz, Cindy L et al. (2015) Patterns of relapse from a phase 3 Study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children's Oncology Group. Int J Radiat Oncol Biol Phys 92:60-6
Dharmarajan, Kavita V; Friedman, Debra L; FitzGerald, T J et al. (2015) Radiotherapy quality assurance report from children's oncology group AHOD0031. Int J Radiat Oncol Biol Phys 91:1065-71
Servaes, Sabah; Khanna, Geetika; Naranjo, Arlene et al. (2015) Comparison of diagnostic performance of CT and MRI for abdominal staging of pediatric renal tumors: a report from the Children's Oncology Group. Pediatr Radiol 45:166-72

Showing the most recent 10 out of 60 publications